Type II and IV subjects, LDL apolipoprotein B (apo B) synthesis was greater than normal. In Type IV, the VLDL triglyceride/apo B ratio was normal and almost all of the LDL apo B was derived from VLDL. LDL cholesterol/apo B ratio was diminished and LDL apo B fractional catabolic rate (FCR) was sufficiently increased to prevent a rise in plasma LDL concentration. In Type II, VLDL triglyceride/apo B was reduced and 14% to 50% of the LDL was formed by direct synthesis. LDL cholesterol/apo B was normal and LDL apo B FCR was lower than in Type IV subjects. In four patients whose plasma lipid levels became normal with carbohydrate restriction and intake of a fibric acid derivative, plasma VLDL and LDL composition and LDL kinetic measurements remained unchanged. By contrast, VLDL triglyceride-apo B decreased and direct LDL syntheseis increased in four patients whose phenotype changed to Type Ha. LDL cholesterol/apo B also increased and LDL FCR declined. Among patients with FCHL, significant correleations between VLDL triglyceride/apo B, LDL apo B derived by direct synthesis, LDL cholesterol/apo B, and LDL apo B FCR were found. Thus, increased apo B synthesis is a characteristic feature of FCHL. The phenotypic expression is determined by the availability of triglyceride for hepatic coupling to apo B which could influence the source, composition, and removal rate of circulating LDL. Despite normalization of their plasma lipid levels, some patients continued to show the compositional and kinetic features of FCHL.
F amilial combined hyperlipidemia (FCHL) is a recently recognized disorder associated with an increased risk of coronary heart disease and characterized by multiple lipoprotein phenotypes. 12 Among affected family members, some have an increase in plasma very low density lipoprotein (VLDL) (Type IV hyperlipoproteinemia); some have an elevation in plasma low density lipoprotein (LDL) (Type I la); and the remainder have an increase in both VLDL and LDL (Type Mb). Even in the same individual, changes in the plasma lipoprotein pattern have been reported, 3 and we have also observed phenotypic changes in some FCHL patients during hypolipidemic therapy.
Although a genetic marker for FCHL has not yet been identified, kinetic studies reveal specific abnormalities that distinguish the disorder from familial hypertriglyceridemia and familial hypercholesterolemia. In subjects with FCHL, VLDL triglyceride and apolipoprotein B (apo B) synthesis are proportionately increased, resulting in enhanced secretion of VLDL particles of normal composition. 4 -6 Conversion of VLDL apo B to LDL is increased, 6 ' 7 and in some patients LDL turnover may also be enhanced. 5 In familial hypertriglyceridemia, the increase in VLDL triglyceride synthesis is relatively greater than apo B, resulting in formation of triglyceride-enriched VLDL particles. 4 ' 6 Less than 50% of VLDL apo B is converted to LDL, and most of the VLDL apo B is presumably removed from plasma as remnant particles. 6 ' 7 In familial hypercholesterolemia, VLDL apo B synthesis is usually normal, 5 while LDL synthesis is on the high side of normal or increased. LDL fractional removal rate, however, is markedly reduced. 58 - 11 To examine the mechanism of the varying lipoprotein phenotypic expressions in FCHL, we performed kinetic studies of plasma LDL transport and determined the relationship of the kinetic measurements to the LDL source and plasma VLDL and LDL composition. The subjects were 11 untreated FCHL patients with different lipoprotein phenotypes and eight patients whose lipoprotein pattern changed after reduction of plasma triglyceride concentration by carbohydrate restriction and intake of a fibric acid derivative.
Methods

Subjects
Kinetic studies were performed on 11 untreated FCHL patients: five with Type IV, three with Type lib, and two with Type I la lipoproteinemia. Eight patients underwent repeat studies after the successful reduction of their plasma triglyceride concentrations by 4 to 12 months of carbohydrate restriction and intake of a fibric acid derivative (clofibrate and gemfibrozil). Four patients were selected because their lipoprotein profile changed from Type IV to normal; another four were selected because their profile changed from Type IV or Mb to Type Ma. Subjects demonstrated a consistent lipoprotein profile and steady-state plasma lipid and lipoprotein levels before and during the kinetic study period.
Patients were recruited from the families in the community who had participated in our previous research. 6 Plasma lipids and lipoprotein levels were determined in all first-degree relatives (ascertainment was 80% or more). Subjects were diagnosed as having FCHL when one family member had hypertriglyceridemia and Phenotype IV, one subject had hypercholesterolemia and Phenotype Ha, and one had elevation of both lipids and Phenotype lib. Patients who had no living relatives or too few to enable identification of the genetics of their hyperlipidemia were excluded. Subjects who had four or more adult, first-degree relatives with normal plasma lipid levels were considered to have unclassified hyperlipidemia and were not included. These criteria are similar to those previously described. 13 Six patients (Subjects 24, 26, 61, 62, 63 and 64) had a history of myocardial infarction proven by electrocardiogram and enzyme measurements, but their condition was stable and they were on no medication for 3 to 6 months before the study. All patients had a strong family history of coronary and/or peripheral vascular disease. None, however, had xanthoma or xanthelasma.
Plasma lipid levels and lipoprotein profiles were determined in at least three sessions before admission into the study. Hypertriglyceridemia and hypercholesterolemia were considered to be present when the plasma lipid level exceeded the 90th percentile of a similarly aged normal population. 12 > 13 Lipoprotein phenotyping was performed by quantitative analysis of triglyceride and cholesterol content of plasma VLDL and cholesterol content of LDL separated by ultracentrifugation. Type IV hyperiipoproteinemia was diagnosed when the hyperlipidemia was due to an elevation of plasma VLDL alone. Type Mb was recognized when the increase in plasma VLDL was accompanied by an increase in LDL cholesterol. Type Ha was diagnosed when the increase in LDL cholesterol was associated with normal plasma VLDL concentration. No plasma showed a broad i beta band on electrophoresis or cholesterol/trigly-i ceride ratio in plasma VLDL greater than 0.3.
Routine laboratory studies were performed to exclude abnormal thyroid, liver, or kidney function. Patients with marked obesity (> 150% of ideal body weight), acute illness, a history of major surgery, abnormal glucose tolerance, or a history of excessive alcohol consumption were also excluded. All subjects were Caucasian.
Data were compared to those obtained in 13 (eight male, five female) healthy volunteers of similar age and normal plasma lipid levels. Table 1 shows the clinical characteristics of the study groups. Although patients in the FCHL group were slightly heavier than the normolipemic controls, their obesity level (percentage of ideal body weight as determined from the Metropolitan Life Insurance Company tables for the midpoint of the range for medium body frame) was not significantly different from the normal subjects. Individual data for the normal group has been previously published. 6 
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Study Protocol
Untreated FCHL patients were advised to adhere to a weight-maintaining diet providing 40% of the calories as carbohydrate, 40% as fat, and 20% as protein for 2 to 4 weeks before their participation in the study. The polyunsaturated/saturated fat ratio in the diet was approximately 0.4 and the cholesterol intake was 600 mg/day. The subjects were subsequently admitted to the Metabolic Unit or to the Clinical Research Center and their dietary intake was maintained for 2 to 4 weeks before the kinetic investigation. Fasting blood samples were obtained twice a week for lipoprotein analyses. A similar protocol was applied to the control group. In the post-treatment study, carbohydrate intake was reduced to 25% to 30% and protein intake was increased to 30% to 35% of the total calories. Patients were also given gemfibrozil (1200 mg/day) or clofibrate (2 g/day) and were repeatedly examined in the outpatient clinic. During the period of admission to the Clinical Research Center, blood samples were obtained twice weekly. Repeat studies were performed as long as the patient's medication was continued.
During the first 48 hours of the kinetic study period, patients received a diet containing their usual caloric intake with a reduction of fat content to 5 g/day. Food was served in five equal meals at 8:00 a.m., 11:00 a.m., 2:00 p.m., 5:00 p.m., and 8:00 p.m. Total plasma lipids, VLDL triglyceride, and LDL cholesterol were determined every other day. Lugol's iodine (5 drops/day) was given 2 days before and throughout the investigation to prevent thyroid uptake of radioactive iodine. The nature of the investigation was explained and informed consent was obtained from each patient. The study was approved by the institution's Human Research Review Committee.
Procedures
Plasma LDL apo B fractional catabolic rate (FCR) and synthetic rate (SR) were determined from plasma radioactivity curves following injection of the patient's own plasma LDL labeled with 1 2 5 I . 9 1 4 After an overnight fast, approximately 100 ml of venous blood was withdrawn using EDTA (1 mg/ml) as an anticoagulant. Plasma LDL (d = 1.019-1.063) was isolated by ultracentrifugation. 15 The lipoprotein fraction was dialyzed against several changes of 0.9% saline containing 0.1% EDTA. LDL was then labeled with 125 I using the iodine monochloride jet technique modified to introduce 0.5 to 1.0 atoms of iodine per mol of lipoprotein. 16 Unbound 125 I was removed by gel chromatography followed by repeated dialysis against 6 to 8 changes of 0.9% saline. The iodinated material was sterilized by millipore filtration and then mixed with sterile human albumin to prevent radiodestruction of the lipoprotein. All procedures were carried out under strictly sterile conditions. After overnight fasting, each patient received a pulse injection of 12S I-LDL (10 to 15 mg protein and 60 to 100 /iC\) diluted in sterile saline. Blood samples were withdrawn 10 minutes after the injection, at 1hour intervals for the first 12 hours, every 2 hours for an additional 8 hours, and then every 4 to 8 hours for the next 24 hours. Fasting blood samples were also obtained daily for a total period of 2 to 3 weeks.
Plasma LDL (d = 1.019-1.063) was quantitatively isolated from each sample by standard ultracentrifugation procedures. 15 The LDL fraction was subsequently washed by floatation through two volumes of density solution of 1.063 g/ml. Selective precipitation of the apo B was then achieved by adding an equal volume of tetramethylurea (TMU). 17 The precipitate recovered on glass fiber discs by filtration was washed with equal volumes of physiological saline and TMU, followed by distilled water and then chloroform/methanol (1:1, vol/vol). The TMU precipitate was counted together with 125 I-LDL standards to allow correction for radioactivity physical decay. After the radioassay, the apo B precipitate was solubilized in NaOH and the protein content was determined. 18 The protein content was estimated using bovine albumin as a reference standard. No chromogenicity factor was used since purified apo B, determined by gravimetry and corrected for its carbohydrate content, has been shown to give identical readings to anhydrous bovine albumin. 17 Recoveries of LDL apo B mass and radioactivity during the TMU precipitation procedure were corrected for using the LDL apo B content determined according to the standard procedure of Kane et al. 17 (LDL apo B = total LDL protein -TMU-soluble protein). Correction for incomplete recovery during the LDL washing procedure was based upon measurement of cholesterol in the initial LDL density spin and in the final preparation processed for TMU precipitation. Using 125 I-LDL samples from normal and hyperlipemic subjects added to the same patient's plasma and reisolated by ultracentrifugation, the overall recovery of LDL apo B during the initial ultracentrifugation step and washing was 82% to 87%.
The 125 I radioactivity present in LDL per liter of plasma was expressed as a percentage of the radioactivity dose injected into each patient and was plotted versus time on a semilogarithmic scale. Plasma LDL apo B fractional catabolic rate (FCR) was determined from the 12S I-LDL disappearance curve using the two-compartment model of Matthews. 19 The total plasma LDL apo B synthetic rate (total SR) in mg/kg/ day = FCR (<j-1 ) x steady-state LDL pool (mg) ,.> body weight (kg)
The steady-state pool was calculated from the mean plasma LDL apo B concentration determined in 12 to 14 samples obtained during the kinetic study period and the plasma volume determined from the initial distribution space of labeled LDL. For calculating the LDL apo B synthetic fraction derived from VLDL (SR from VLDL), each patient received a simultaneous injection of 131 I-VLDL; then plasma 131 I-VLDL and 131 I-LDL were determined. Details of this procedure have been described previously. 6720 Briefly, the patient's own plasma VLDL was isolated by ultracentrifugation at density < 1.006, and then labeled with 131 I. After removal of unbound radioiodine and sterilization by millipore filtration, approximately 4 to 8 mg of VLDL apo B protein containing 40 to 60 fjiC'i of 131 I were diluted in saline and given as a pulse injection. Plasma samples were obtained at time intervals, and plasma VLDL and LDL apo B mass and 131 I radioactivities were measured as described above. The fraction of LDL apo B formed from VLDL was calculated from the ratio of 131 I to 125 I-LDL, when the 131 I and 125 I disappearance curves became parallel. In this calculation, it is assumed that the 125 I-LDL reflects a 100% conversion to LDL. Since the 125 I-LDL given intravenously was in the patients' circulation for a longer time than the 131 I derived from VLDL, this ratio was calculated from the 12S I-LDL curve at time t and that of 131 
Because of inaccuracies due to the deconvolution analysis, 21 nonhomogeneity in decay rates of particles within the VLDL, and possibly the LDL compartments, 22 the estimates of direct LDL apo B synthesis are approximations. This estimate represents the fraction of LDL apo B unaccounted for by kinetic analysis of VLDL conversion to LDL and does not necessarily prove direct hepatic synthesis of apo B into LDL particles (see Discussion).
Other Methods
Total plasma triglyceride and cholesterol were measured in venous blood after overnight fasting using standard Lipid Research Clinic Autoanalyzer II semi-automated techniques. 23 Plasma VLDL and LDL were quantitatively isolated by ultracentrifugation and VLDL triglyceride and cholesterol and LDL cholesterol were determined. Plasma VLDL and LDL apo B were measured in TMU precipitates as described above.
Statistical Procedures
Comparison between groups was assessed using Student's f test for unpaired data. Comparison between pretreatment and post-treatment values were determined by Student's /test for paired data. Correlations were evaluated by regression analysis using the Statistical Package for Social Sciences manual. Results are presented as means ± SEM. Table 2 shows that total LDL apo B synthesis in untreated FCHL patients of both Type IV (27.1 + 1.5 mg/kg/day) and Type II (30 ± 2.3 mg/kg/day) was significantly greater than normal (13.2 ± 1.0 mg/kg/ day). No significant difference in LDL apo B SR was observed between the Type IV and Type II subgroups. LDL apo B FCR in Type IV subjects was also greater than normal (0.77 ± 0.02 versus 0.42 ± 0.02 d~1), thus plasma LDL concentration was within the normal range. In Type II patients, LDL apo B FCR (0.53 ± 0.04-1 ) was higher than normal, but this increase was significantly lower than that of Type IV patients. Plasma LDL level, therefore, was increased.
Results
In both Type IV and Type II subgroups ( Table 2) , formation of LDL from VLDL apo B (26.8 ± 1 . 1 and 21.5 ± 2.3 mg/kg/day, respectively) was significantly increased above normal (13.6 ± 0.8 mg/kg/day). In Type IV patients, as in the normal subjects, formation of LDL from VLDL accounted almost completely for total LDL synthesis, and only a minor fraction (0.8 ± 2.3%) was derived from non-VLDL sources (direct synthesis). In Type II patients, on the other hand, total LDL apo B production was significantly greater than the LDL apo B fraction derived from VLDL (p < 0.05) (14% to 50% was directly synthesized). The mean VLDL TG/apo B ratio in Type IV FCHL (10.4 ± 0.62) was not significantly different from normal (10.5 ± 0.38, p > 0.05) but in Type II, this ratio was significantly reduced (8.1 ± 0.29, p < 0.01). The LDL CH/apo B ratio in the Type IV FCHL patients (1.44 ± 0.04) was significantly lower than that of normal subjects (1.90 ± 0.09). In Type II patients, on the other hand, LDL cholesterol and apo B were proportionately increased; hence the cholesterol/apo B ratio (1.9 ± 0.08) was similar to normal (Tables 1 and 2 ). Although the absolute values for the cholesterol/apo B ratio might differ from those previously reported in FCHL, the pattern of change characteristic of each of the phenotypic forms is essentially similar. 3 Tables 3 and 4 and Figure 1 show plasma lipid levels and plasma VLDL and LDL composition in the eight FCHL patients who were reinvestigated following a carbohydrate-restricted diet and treatment with gemfibrozil or clofibrate. A decline in total plasma triglyceride, VLDL triglyceride, and VLDL apo B was observed in all subjects. Four Type IV patients showed a concomitant decrease in total plasma cholesterol and their plasma lipids and lipoprotein concentrations following therapy were within normal limits. In two Type IV and two Type lib patients, total plasma cholesterol and LDL cholesterol were paradoxically increased and their lipoprotein pattern changed to Type Ha.
In the four FCHL patients whose plasma lipid levels normalized with hypotriglyceridemic therapy, plasma VLDL triglyceride and apo B were equally reduced so that their triglyceride/apo B ratio was unchanged. LDL cholesterol/apo B ratio was also unaffected by therapy. In the four subjects whose lipoprotein profiles changed to Type Ma, the ratio of triglyceride to apo B in VLDL decreased from 9.0 ± 0.04 to 7.2 ± 0.3, and the ratio of cholesterol to apo B in LDL increased from 1.66 ± 0.1 to 1.91 ± 0.04.
Total LDL apo B synthesis in the four subjects who achieved normal plasma lipid levels was not significantly different from pretreatment values (29.1 ± 1.2 vs 26.9 ± 2.9 mg/kg/day). LDL apo B synthesis from VLDL apo B was also similar to pretreatment values (27.4 ± 1.2 vs 26.3 ± 1.5 mg/kg/day), and largely accounted for the total LDL apo B synthesis. LDL apo B FCR in these subjects was unchanged (0.71 ± 0.01 vs 0.76 ± 0.04 d-1 ). The total LDL apo B synthesis in the four patients whose lipoprotein phenotypes changed to Ha was also not significantly Figure 2 shows that in the FCHL group as a whole (including the pre-and post-treatment measurements), a significant negative correlation between the VLDL TG/apo B ratio and the fraction of LDL apo B derived by direct synthesis was found. A significant positive correlation between the directly synthesized LDL apo B fraction and LDL cholesterol/apo B ratio and a negative correlation between the LDL cholesterol/apo B ratio and LDL apo B FCR were also observed.
Discussion
Our study of LDL metabolism in FCHL suggests three major conclusions: 1) regardless of the lipoprotein phenotype, FCHL is characterized by greatly enhanced LDL apo B synthesis, presumably due to the unrestricted overproduction of apo B; 2) hepatic coupling between triglyceride and apo B production determines the source of circulating LDL (VLDL derived versus direct synthesis) and the composition of the LDL particles, which in turn influences LDL FCR and hence the phenotypic expression of the disorder; 3) normalization of plasma lipid levels with diet and hypolipidemic drugs creates a subpopulation of subjects who, despite normal plasma lipid levels, continue to exhibit the LDL compositional and kinetic features of FCHL.
An increase of VLDL apo B synthesis in FCHL has been suggested by previous studies. 4 -8 The present study reveals that the LDL apo B synthetic rate is also increased and that this increase can be observed in Type IV, Type lla, and Type lib subjects. That unrestricted overproduction of apo B is a feature of FCHL is supported by the following: 1) the increase in LDL apo B synthetic rate was found in all subjects, irrespective of prevailing plasma VLDL or LDL concentrations; 2) the increase in LDL apo B synthetic rate was unresponsive to diet and drug therapy, which in other forms of hyperlipidemia result in reduced VLDL and LDL turnover; 24 -26 3) in a preliminary report, we observed 27 that in two subjects with extreme lipemia and FCHL, reduction of circulating apo B mass by plasmapheresis resulted in a rebound increase in VLDL apo B production, suggesting an abnormality in the feedback regulation of apo B synthesis. Initial studies of apo B transport in humans 2028 suggested that all apo B is secreted into the plasma with VLDL, which is subsequently metabolized to form LDL particles. Recently, however, it has become apparent that apo B may be associated with LDL without prior formation of VLDL. This alternate pathway may involve direct secretion of apo B into LDL or into intermediate density lipoprotein (IDL) and/or a rapidly turning over pool of VLDL particles that are also converted to LDL. 29 Although this pathway may not be important in normal subjects, it assumes a significant role in patients with familial hy-percholesterolemia 711 and in some patients with FCHL or unclassified hyperlipidemia. 7 Our results show that in FCHL, direct secretion of apo B into LDL accounts for a variable proportion (0% to 56%) of total LDL apo B synthesis and that the magnitude of this pathway varies according to the phenotype of the disease. Whereas in Type IV almost all of the LDL apo B was derived from VLDL, in Type lla and Mb a significant proportion of apo B was directly synthesized into LDL.
The inverse correlation between the VLDL triglyceride/apo B ratio and the directly synthesized LDL apo B fraction suggests that hepatic coupling of triglyceride to apo B production may be an important factor determining the source of circulating LDL. Previous research 48 indicates that the plasma VLDL triglyceride/apo B ratio correlates with their relative synthetic rates. In normal subjects receiving a balanced diet, hepatic coupling of triglyceride to apo B appears to be well integrated and most of the apo B is secreted together with triglyceride and, presumably, cholesterol into plasma VLDL. 614 This coupling, however, may be modified under certain circumstances, such as high carbohydrate feeding, in which the secretion of large VLDL particles highly enriched in triglyceride relative to apo B occurs. 3031 Similarly, in patients with familial hypertriglyceridemia, overproduction of triglyceride and a proportionately smaller increase in apo B synthesis results in the enhanced formation of triglyceride-rich VLDL.* 6 Conversely, a decrease in the availability of triglyceride (as in patients maintained on a hypocaloric diet 32 ) or an increase in cholesterol production (such as in patients with homozygous familial hypercholesterolemia 33 ) results in a significant proportion of apo B being directly synthesized into IDL and/or LDL. 7 ' 11 In patients with Type IV FCHL, triglyceride and apo B synthetic rates were equally increased and thus, the VLDL triglyceride/apo B ratio was normal. Almost all of the apo B was coupled to triglyceride and secreted with VLDL. In Type II patients, on the other hand, formation of apo B was relatively greater than triglyceride. A portion of apo B was incorporated into triglyceride-poor VLDL particles and the remaining apo B fraction was synthesized directly into LDL.
Coupling of triglyceride to apo B could influence the structure and composition of plasma LDL in two ways: 1) by affecting the proportion of apo B that is preferentially coupled to cholesterol instead of triglyceride and consequently, the site of apo B entry into the VLDL-LDL density ranges; 2) by affecting the triglyceride load presented to the lipolytic cascade which normally catalyzes the conversion of VLDL to LDL, during which the VLDL particle is gradually depleted of triglyceride and at the same time acquires cholesterol. We propose that differences in hepatic availability of triglyceride relative to cholesterol, together with increased apo B synthesis, influence the source, the density distribution, and the composition of the LDL particles, and, hence, might account for the lower LDL cholesterol/apo B ratio in Type IV compared to Type II FCHL.
In Type IV FCHL patients, the increase in LDL apo B synthesis was associated with greatly enhanced LDL apo B removal, and thus the plasma LDL concentration was within the normal range. Although LDL apo B removal was also increased in Type II patients, LDL apo B FCR was lower than that of Type IV patients, resulting in an increase in plasma LDL level. The lower FCR in Type II compared to Type IV subjects may relate to the higher LDL cholesterol/ apo B ratio in the former group, since for the same number of apo B molecules removed by the LDL receptor, a greater amount of cholesterol would be internalized. This could down-regulate the LDL receptor 34 and limit a compensatory increase in LDL catabolism in response to increased LDL flux into the plasma. Janus et al. 5 have previously reported increased LDL apo B synthesis in patients with FCHL. In contrast to our findings, however, they observed no significant differences in LDL apo B FCR between FCHL and normal subjects. There also was no obvious distinction in the FCR between FCHL patients with normal and those with elevated LDL concentrations. At present we cannot explain this discrepancy although it may relate to differences in patient selection and/or heterogeneity in LDL kinetics among individuals affected with this disorder.
Our results suggest that in FCHL, the coupling of triglyceride to apo B production, together with enhanced apo B synthesis, could influence the source of plasma LDL, the LDL cholesterol/apo B ratio, the efficiency of LDL removal, and the lipoprotein phenotype. This sequence is supported by the following: 1) The inverse correlation between VLDL triglyceride/ apo B ratio and directly synthesized LDL fraction; the positive correlation between the directly synthesized LDL fraction and the LDL cholesterol/apo B ratio; and the negative correlation between the LDL cholesterol/apo B ratio and the LDL apo B FCR observed in the group as a whole (Figure 2) ; 2) the directional changes in VLDL triglyceride/apo B ratio, directly synthesized LDL fraction, LDL cholesterol/ apo B ratio, and LDL apo B FCR found in patients whose lipoprotein phenotype changed to Ma during therapy as compared to those whose lipoprotein profile was normalized (Figure 1 ).
An interesting observation is that the four subjects whose serum lipid levels became normal with therapy continued to show an increase in LDL apo B synthetic rate, a decrease in LDL cholesterol/apo B ratio, and an increase in LDL apo B FCR just as patients with Type IV FCHL. These compositional and kinetic features are similar to those reported in some normolipemic subjects with coronary heart disease. 35 ' x These findings suggest the possibility that some individuals designated as normolipemic, high coronary heart disease risk subjects could represent a subpopulation of FCHL patients in whom the expression of the disease has been modified by dietary intake or other unknown factors. Thus, our results raise the intriguing question of whether FCHL is a single disorder in which treatment serves to reduce the variance in its expression, or whether FCHL results from a combination of disorders, perhaps familially aggregated, that can be sorted pharmacologically by hypotriglyceridemic therapy. Both genetic studies and detailed kinetics in which all of the metabolic pathways of plasma VLDL and LDL subtractions are accurately defined should provide further insight into this issue.
Finally, our data support the hypothesis that overproduction of apo B, with or without hyperlipidemia, is a common feature of several atherogenic disorders including familial hypercholesterolemia, 11 mild hypercholesterolemia, 37 noninsulin-dependent diabetes mellitus, 14 obesity, 1438 the normolipemic hyperapobetalipoproteinemia syndrome, 38 and FCHL. Recognition of the molecular processes underlying the enhanced apo B synthesis in these disorders should enhance our understanding of the mechanism of atherogenesis in humans.
